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Abstract
Migraines are the third most common disease in the world, with an estimated global 
prevalence of 14.7%. Migraine has a characteristic throbbing quality, of moderate to severe 
intensity, generally unilateral, and has associated symptoms including photophobia, 
phonophobia, and gastrointestinal distress. Episodic migraine occurs less than 15 days 
per month, while chronic migraines occur more or equal to 15 days per month. Treatment 
of migraine consists of abortive and preventive therapy. Acetaminophen, aspirin, and 
NSAIDs are often used for management of mild attacks. For more severe attacks, trip-
tans are recommended. Intravenous administration of some combination of dopamine 
receptor agonists, dihydroergotamine, and intravenous NSAIDs is recommended for 
severe episodes. Preventive daily treatment of migraine is recommended when migraine 
episodes exceed 6–8 days per month, or what is tolerable to the patient. Beta-blockers, 
topiramate, amitriptyline, and divalproex sodium are commonly used for migraine pre-
vention. Initial anecdotal reports in patients receiving botulinum toxin for facial cosmetic 
purposes noted the effects of these injections on headache and trigger point-initiated pain 
syndromes, which appeared to be independent of its effects upon muscle tone. Current 
thinking is that migraine pain results from activation of intracranial meningeal perivascu-
lar afferents with some studies suggesting the role of extracranial afferents.
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1. Introduction
Headache is the most common nervous system disorder. Migraine headache is one of the 
most debilitating forms of headache [1]. Together with anemia and hearing loss, the World 
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Health Organization, migraine is one of the three most prevalent conditions but states that 
their affects are not dramatic, is overlooked and underestimated [2]. It affects 2–15% of the 
world’s population for a total of 324.1 million migraine sufferers, not of episodes, with women 
affected three times as often as men and affects mostly socially active and productive people 
ranging from 25 to 55 years of age [3, 4]. The World Health Organization ranks migraine 
headache as the nineteenth most disabling disease and characterizes severe migraine to be as 
disabling as quadriplegia, psychosis, and dementia [1, 2, 5, 6]. Traditional theories regarding 
its cause attribute it to a vascular or central nervous phenomenon. Migraine is a primary 
headache, classified by the International Headache disorder in which the headache is by itself 
the illness. Migraine is characterized by severe headaches and is often associated with nau-
sea, vomiting, and heightened sensitivity to sound and light at the peak of the attack. Many 
migraneurs even when they have consulted a physician are not satisfied with their therapy 
and report that typically prescribed medications are not always optimal. Currently, triptan 
medications are the most effective therapy for acute migraine attacks, reducing pain and asso-
ciated symptoms in only up to two-thirds of patients. There is a significant need to develop 
more effective therapies for migraine prevention because up to 35% of affected persons suf-
fers from 2 to 3 severe attacks per month and 25% suffers more than 4 attacks per month [7].
Patients eligible to be considered for prophylactic migraine treatment include frequent head-
aches, recurring disabling migraines that significantly interfere with daily routine, excessive 
cost of acute and preventive treatments, failure, contraindication overuse or adverse events 
with acute migraine therapy, patient preference, and presence of uncommon migraine con-
ditions including hemiplegic migraine, basilar migraine, migraine with prolonged aura, or 
migrainous infarction [8].
Commonly used treatments for migraine prophylaxis include β-adrenergic blockers, calcium 
channel blockers, tricyclic antidepressants, and anticonvulsants, most of them with moderate 
to severe adverse effects. Botulinum toxin type A has been under use for the treatment of 
migraine and other types of headache. Botulinum toxin type A has been used to treat a variety 
of disorders including involuntary muscle contraction, blepharospasm, strabismus, cervical 
dystonia, and for cosmetic purposes [9]. Specifically for the treatment of dystonia and spastic-
ity, botulinum toxin type A has shown an analgesic effect, leading to further investigation for 
other painful conditions such as migraine and tension-type headache.
Botulinum toxin type A has been used off-label since 2000 for the treatment of migraine head-
ache [10]. Since then, multiple small trials report the effectiveness of botulinum toxin type 
A for migraine headache prevention. However, the Phase III Research Evaluating Migraine 
Prophylaxis Therapy (PREEMPT) 1 and 2 trials that class 1A evidence was concluded that 
botulinum toxin type A treatment reduces chronic migraine headache impact and improves 
headache-related quality of life [11–13]. After these evidence-based data were published, the 
Food and Drug Administration in the United States approved botulinum toxin type A for the 
treatment of chronic migraine headache on October 15, 2010.
Botulinum toxin has been investigated for the treatment of several headache disorders. The 
beneficial effect of botulinum toxin type A treatment for migraine was first noted in patients 
who were given the protein for cosmetic purposes treating facial rhytides and reported relief 
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from their migraine headaches [14, 15]. The pooled result of these studies showed that botuli-
num toxin type A was significantly superior to placebo in reducing headache days and mul-
tiple quality-of-life measures [16, 17].
2. Migraine
Cephalalgia has affected human beings since the beginning of time, being the earliest 
description among Sumerian poems circa 3000 BC, which described an individual as being 
“sick-headed.” The first reports of a patient describing alteration in visual perceptions, 
or aura, came from Hippocrates. During the second century AD, Aretaeus of Cappadocia 
delineated the symptom structure of what is commonly referred to as migraine with aura. 
More recently, scientific theories to explain the pathophysiology of migraine headaches have 
emerged. After the introduction of the neural theory, proposing that certain disturbances 
within the autonomic nervous system may account for the triggering and sustenance of the 
headache. Dey subsequently described the phenomenon of cyclical pituitary compression of 
the trigeminal nerve. In the modern era, Wolff described a phenomenon of episodic extracra-
nial vascular dilatation and constriction, leading to the formulation of the vasogenic theory 
of migraine.
Worldwide prevalence of migraine is estimated to be 13–17% in women and 8–14% in men. 
The effect of migraine on quality of life is profound. Nearly all migraineurs experience 
functional impairment because of their condition; more than half being severe requiring 
bed rest. Most migraine patients do not seek medical attention, instead relying on over-
the-counter medications, because they believe that effective prescribed treatments do not 
exist [19].
Migraine was classified originally as classic or common. In 1988, the International Headache 
Society published guidelines for discriminating among 13 major types of headache because of 
inconsistency of headache definitions and the resulting difficulty in epidemiologic and patho-
physiologic study; classic migraine became “migraine with aura,” and common migraine 
became “migraine without aura.” Migraine can be episodic or chronic but has unique com-
binations of neurologic, gastrointestinal, and autonomic symptoms that differentiate it from 
other headache conditions [19]. In the International Classification for Headache Disorders 
created in 1988 (ICHD-1), major headache types were categorized and distinguished primary 
and secondary headache disorders. Revised in 2003, the ICHD-2 defined a primary headache 
disorder as one for which no identifiable structural or organic cause is known. A second-
ary headache disorder required a known structural or systemic etiology as the cause of the 
headache symptom. Examples of these include intracranial bleeding, thrombosis of cerebral 
veins, infections (e.g., meningitis or encephalitis), tumors, dissection of cerebral arteries, and 
arteritis.
Migraine, tension-type headache, and trigemino-autonomic headache are the most common 
primary headaches. Clinical presentation, medical history, clinical, and technical examina-
tion allow us to distinguish the distinct types of headache disorders. Headache in migraine 
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commonly has pulsating or throbbing character and is unilateral. Attacks last 4–72 h, and 
usually in the moderate to severe presentations are accompanied by photophobia, phono-
phobia, or osmophobia, and nausea or vomiting. Typically, physical activity worsens pain. 
Chronic migraine is defined in the ICHD-2 as migraine headache at least 15 days per month 
for 3 months, with attack duration lasting more than 4 h. Whereas episodic migraine only 
lasts less than 15 headache days per month according to the most recent revision by the 
International Chronic Headache diagnostic criteria in 2014. Other forms of chronic daily 
headache include chronic tension type headache, hemicrania continua, new daily persistent 
headache, and chronic cluster headache.
The spectrum of migraine headaches has been coded by the International Headache Society in 
its last revision (ICHD-III-β-2014) accepted seven subtypes, with notable subforms (Table 1). 
Migraine can be classified into two major subtypes, namely with or without aura. Migraine 
without aura is the most prevalent subtype and may involve a higher frequency of attacks and 
greater disability than migraine with aura.
Migraine is a paroxysmal headache disorder, with periods of relative quiescence between 
acute headache episodes. Headaches typically manifest with moderate to severe throbbing 
head pain lasting hours to days, in a hemicranial and frontotemporal distribution; however, 
bilateral and posterior cervical pain can occur. Associated symptoms may include nausea, 
vomiting, anorexia, malaise, photo- or phonophobia, and blurred vision. Transient neuro-
sensory perceptions prior to or concomitant with the pain phase occur in migraine with aura.
Diagnostic criteria for migraine without aura include at least five attacks, lasting 4–72 h, with 
at least two of the following characteristics: unilateral location, pulsating quality, moder-
ate or severe intensity, aggravation by or cause avoiding of routine activity. Also nausea or 
vomiting or both during the headache of photophobia or phonophobia, in general, cannot be 
attributed to any other disorder.
Approximately 30% of migraineurs experience auras; for migraine with typical aura, criteria 
include at least two attacks including an aura consisting in the presentation of fully reversible 
visual symptoms including positive features (e.g. flickering lights, spots or lines) or negative 
features (loss of vision) or fully reversible sensory symptoms including positive features (e.g. 
pins and needles) or negative features (numbness), or fully reversible dysphasic disturbance. 
Migraneurs also develop at least, two of the following: homonymous visual symptoms or uni-
lateral sensory symptoms, at least one aura symptom developing gradually over greater than 
5 minutes or different aura symptoms occurring in succession over greater than 5 minutes, 
and each symptom lasting greater than 5 minutes and less than 60 minutes. The headache ful-
filling criteria for migraine without aura begins during the aura or following the aura within 
60 minutes must be considered a migraine with typical aura, and as the other classification, it 
cannot be attributed to any other disorder [20].
2.1. Pathophysiology of migraine
The pathophysiology of migraine is complex and is still a focus of research. Contrary to the 
previous vascular theory of migraine, which held that migraine resulted from constriction 
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and dilation of blood vessels innervating the head, migraine is now recognized as result-
ing fundamentally from a hypersensitive central nervous system that has difficulty properly 
modulating pain. In the current neurovascular model, the vascular changes that occur are 
1.1. Migraine without aura
1.2. Migraine with aura
 1.2.1. Typical aura with migraine headache
  1.2.1.1. Typical aura with headache
  1.2.1.2. Typical aura without headache
 1.2.2. Migraine with brainstem aura
 1.2.3. Hemiplegic migraine
  1.2.3.1. Familial hemiplegic migraine
   1.2.3.1.1. Familial hemiplegic migraine type 1
   1.2.3.1.2. Familial hemiplegic migraine type 2
   1.2.3.1.3. Familial hemiplegic migraine type 3
   1.2.3.1.4. Familial hemiplegic migraine, other loci
  1.2.3.2. Sporadic hemiplegic migraine
 1.2.4. Retinal migraine
1.3. Child. Chronic migraine
1.4. Complications of migraine
 1.4.1. Status migrainosus
 1.4.2. Persistent aura without infarction
 1.4.3. Migrainous infarction
 1.4.4. Migraine aura-triggered seizure
1.5. Probable migraine
 1.5.1. Probable migraine without aura
 1.5.2. Probable migraine with aura
1.6. Episodic syndromes that may be associated with migraine
 1.6.1. Recurrent gastrointestinal disturbance
  1.6.1.1. Cyclical vomiting syndrome
  1.6.1.2. Abdominal migraine
 1.6.2. Benign paroxysmal vertigo
 1.6.3. Benign paroxysmal torticollis
Adapted from the International Classification of Headache Disorders-III-β-2014, International Headache Society, 2014.
Table 1. Classification of migraine headache disorders.
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recognized as secondary phenomena. The primary components involve interactions among 
the brainstem, the cortex, and the trigeminovascular system. The brainstem is involved in 
descending modulation of pain, neuronal inhibition that traverses the cortex is the recognized 
cause of migraine aura, and resulting sensitization and activation of trigeminal afferents are 
the source of pain. Culminating from this sequence is a release of neuropeptides, dilation of 
meningeal blood vessels, neurogenic inflammation, and both within attacks and over time 
central sensitization manifests. Intracranial blood vessels and meninges are pain sensitive. 
Sterile neurogenic inflammation may evoke migraine pain.
Neurogenic inflammation includes vasodilation, plasma protein extravasation, mast cell acti-
vation, and release of proinflammatory mediators. The activation of meningeal nociceptors 
releases various neuropeptides, including calcitonin gene-related peptide (CGRP) and sub-
stance P from trigeminocervical nerve endings. CGRP is a potent dilator of cerebral and dural 
vessels and has found to be elevated in migraine attacks. Substance P is involved in plasma 
extravasation in the dura mater during primary headache attacks, and neurokinin receptor 
antagonists can inhibit neurogenic dural inflammation but have not been found to have effect 
in acute migraine attacks. In contrast, a clinical trial with CGRP receptor antagonist was suc-
cessful in treating acute migraine attacks [21]. Also, a sensitization of peripheral and central 
trigeminovascular neurons seems to take place in migraine.
Sensitization of the peripheral trigeminovascular neurons could mediate the throbbing, and 
sensitization of the central trigeminovascular neurons that propel cutaneous allodynia often 
observed during migraine attacks. The pathophysiology influences a cascade of interacting 
events within the nervous system resulting in headache [22, 23].
Another potential mechanism involves the synaptic vesicle glycoprotein 2A protein (SV2A), a 
synaptic vesicle protein isoform with high affinity for botulinum toxin type A that is involved 
in the binding and subsequent internalization of the toxin into peripheral neurons. Botulinum 
toxin interacts with peripheral nociceptive neurons and inhibits release of nociceptive media-
tors from peripheral nociceptors such as glutamate, substance P, and calcitonin gene-related 
peptide.
Migraine runs in families and has a strong genetic component, and the best example is 
familial hemiplegic migraine, an autosomal-dominant subtype of migraine with aura that 
includes motor weakness. Three genetic mutations corresponding to three variants of familial 
hemiplegic migraine have been identified of which genes code for the ion-channel transport: 
CACNA1A on chromosome 19, SCN1A on chromosome 2, and the ATP1A2 gene on chromo-
some 1. However, contributors to other more common forms of migraine have not been firmly 
established [23].
2.2. Treatment of migraine
Typically, medications for acute attacks include simple analgesics or NSAIDs for mild to 
moderate attacks as abortive treatments. For moderate to severe attacks, ergot derivatives 
were originally prescribed but now are replaced by triptans, with a greater receptor specificity 
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and greater effectiveness for more severe attacks. Opioids are reserved for rescue therapy 
when other medications are contraindicated. Acute medications have limited efficacy and 
are only useful for short-term symptom relief, and some of them result also in adverse side 
effects; further, they do not offer prophylactic benefits and have diminished effectiveness if 
taken over long periods of time. Long-term prevention is the preferred treatment approach 
to migraine.
The primary goal of migraine prophylactic treatment is improving quality of life through 
decreased frequency and intensity of headache, improved function and decreased disability, 
and reduced use of medications with improved efficacy of acute therapy. Although some of 
the proposed etiologic factors are out of the patient’s control, such as heredity [24] and cycli-
cal hormone changes in females [25], others are amenable to lifestyle changes. Examples of 
such include stress, smoking, intake of certain foods such as meats and cheeses (high nitrites), 
nuts, chocolate, caffeine withdrawal and alcohol consumption, lack of exercise, sleep pattern, 
quality and duration, and, in females, menstruation, oral contraception, and estrogen replace-
ment therapy. Some medications also have hypothesized to initiate or increase the frequency 
of migraine attacks, such as nitroglycerin, some calcium channel blockers, tetracycline, and 
sildenafil citrate.
Preventive therapy should be offered to patients with migraine reported six or more days 
per month, with four or more days of headache with some impairment or three or more 
days with headache with severe impairment requiring bed rest. Situations in which should 
be considered include patients with 4–5 migraine days per month, with 3 days with some 
impairment or 2 days with severe impairment [4]. Currently, anticonvulsants, antidepres-
sants, beta-blockers, calcium channel antagonists, conventional or selective nonsteroidal 
anti-inflammatory drugs, and serotonin antagonists have been used as prophylactic treat-
ments for migraine. Unpleasant side effects can occur with each of these types of drugs. They 
include drowsiness, fatigue, dizziness, sexual dysfunction, weight gain or loss, constipation, 
nausea, dry mouth, and insomnia. None of the abovementioned drugs have been approved 
by the US Food and Drug Administration or labeled as such for use in headache treatment 
or prevention [26].
There exists a great demand for long-acting acute and prophylactic therapies that are effec-
tive, well tolerated, and devoid of significant systemic toxicities or adverse effects. The inter-
est in the use of botulinum toxin type A as an alternative therapy has gained popularity.
3. Botulinum toxin and chronic migraine
There are seven botulinum toxin serotypes (A, B, C1, D, E, F, and G) with an eighth serotype 
(H) described by some authors as a hybrid of known serotypes F and A [27]. All serotypes 
inhibit acetylcholine release, although their intracellular target proteins, physiochemical char-
acteristics, and potencies are different. Botulinum toxin type A has been the most widely used 
and studied for therapeutic purposes.
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Botulinum toxin binds to the motor and sympathetic nerve terminals. It enters the nerve 
terminals and inhibits the release of acetylcholine. This inhibition occurs as the botulinum 
neurotoxin cleaves one of several proteins integral to the successful docking and release of 
acetylcholine from vesicles situated within nerve endings. This results in blocking neuro-
muscular transmission at the neuromuscular junction. After direct intramuscular injection, 
botulinum toxin produces partial chemical denervation and paralysis of the muscle, resulting 
in a decrease of muscle activity [28].
The precise mechanism by which botulinum toxin type A alleviates headache pain is unclear, 
but the inhibition of release of glutamate and other neuropeptides suggests that its antino-
ciceptive properties are distinct from its neuromuscular activity. A peripheral trigger point 
theory emerged when Binder first noticed the positive effect of onabotulinumtoxin-A while 
conducting clinical trials for frontal lines and noticing that frontal migraine symptoms 
improved with either corrugator supercilii muscle paralysis by botulinum toxin type A 
injection or corrugator muscle resection for the treatment of hyperfunctional facial lines [18, 
29–30]. Nonsurgical treatment of migraines includes avoidance of triggers, such as alcohol 
and caffeine, and pharmacologic control with medications [31]. Current data suggest that 
botulinum toxin type A modifies the sensory feedback loop to the central nervous system by 
clocking intrafusal fibers, resulting in decreased activation of muscle spindles. This effectively 
alters the sensory afferent system by reducing the traffic along IA spindle afferent fibers [32]. 
Botulinum toxin type A also appears to inhibit the release of glutamate and calcitonin gene-
related peptide from primary nociceptive fibers, reduce the firing of wide-dynamic range 
neurons within the dorsal horn of the spinal cord, and reduce the activity of central nocicep-
tive neurons, as demonstrated by decreased expression of immediate early genes (c-Fos) after 
nociceptor stimulation [28]. A reduction in afferent sensory activity coming from pericranial 
and cervical muscles and inhibition of peripheral and central trigeminal sensitization may 
be the potential mechanisms by which botulinum toxin type A exerts its therapeutic effect in 
migraine, tension-type headache, and other primary headache disorders [33].
Jakubowski explored neurologic markers that might distinguish migraine patients who would 
benefit from botulinum toxin treatment from those who would not. The prevalence of neck 
tenderness, aura, photophobia, phonophobia, osmophobia, nausea, and throbbing was simi-
lar between responders and nonresponders. However, during clinical investigation of pain 
semiology, 92% of nonresponders describes a build-up of pressure inside their head or an 
exploding headache. Among responders, 74% described their head to be crushed, clamped, or 
stubbed by external forces, what we understand as imploding headache, and 13% perceived 
an eye-popping pain (ocular headache). Exploding headaches could explain the pain media-
tion by intracranial innervation; thus, we infer that extracranial botulinum toxin application 
will not correspond to a responsive individual. Imploding and ocular headaches respond to 
botulinum neurotoxin application, suggesting that the migraine pain involves extracranial 
innervation as well [34].
The physiologic mechanism of migraine treatment suggested by Guyuron is the decompres-
sion of peripheral nerves, decreasing peripheral nerve inflammation and excitability, leading 
to newer treatment techniques such as migraine surgery. Botulinum toxin exerts its mecha-
nism chemically, whereas surgery releases such anatomical entrapments mechanically [15].
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4. Patient evaluation
A correct diagnosis of patients presenting with chronic headache requires a systematic 
approach to obtain the necessary information. This may be difficult because of the anxiety, 
feeling of helplessness, and other mood disorders that obscure migraine symptoms. A careful 
interview and documentation of headache history and examination can aid in reaching a 
precise diagnosis and classification.
During the interview, some descriptors will guide in precise identification, such as progres-
sion of headache through present time, age of onset, frequency and duration of the attacks, 
severity of headache episodes, quality of the pain, presence or absence of aura, inciting fac-
tors, mitigating factors, systemic reactions, craniofacial disorders, systemic illnesses, medica-
tion history, family history of headache, and social history.
Although the patient only complains primarily of cranial discomfort, a complete physical 
examination is warranted on the initial visit. Cardiovascular, ophthalmologic, or neuromus-
cular symptoms could be missed; ear, nose, throat, scalp, and neck should be thoroughly 
examined. Specific aspects of the physical examination that should be systematically exam-
ined include: vital signs and affect, cardiopulmonary evaluation, auscultation of the carotid, 
vertebral arteries, cranium and orbits for bruits, range of motion, tenderness, crepitus of the 
neck, and jaw/temporomandibular joint. The head, neck, and back should be palpated for 
trigger points, masses, bruises, or thickened or tender blood vessels. Neurological examina-
tion should rule out papilledema and focal signs, such as visual field deficits, pupillary asym-
metry, sensory deficits of the face, trunk, or extremities; asymmetric gait or motor weakness.
Ancillary tests may provide additional clinical information. Neuroimaging in the form of 
computed tomography (CT) or magnetic resonance imaging (MRI) has become an invaluable 
resource for physical diagnosis. Lumbar puncture may be indicated during a severe head-
ache to detect subarachnoid hemorrhage or meningitis, and can be diagnostic of meningeal 
carcinomatosis or lymphomatosis, and to detect high or low cerebrospinal fluid pressure. 
Electroencephalography (EEG) has been used to screen for structural cerebral abnormali-
ties via the detection of altered electrophysiological patterns, but the American Academy 
in Neurology failed to find in 1995 sufficient evidence supporting the utility of EEG in the 
routine evaluation of headache. If clinical evidence suggests the possibility of organic brain 
pathology, only CT and MRI are suggested [20].
5. Safety, indications, and contraindications
According to the Food and Drug Administration in the United States, botulinum toxin type A 
is indicated for the prophylaxis of headaches in adult patients with chronic migraine. Safety 
and effectiveness have not been established for the prophylaxis of episodic migraines.
Adverse effects are most commonly related to the injection, with systemic adverse effects 
being very rare. Injection-related adverse effects are mild and transient and rarely lead to 
discontinuation of therapy.
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Serious and/or immediate hypersensitivity reactions have occurred, including anaphylaxis, 
serum sickness, urticarial, soft tissue edema, and dyspnea.
Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or 
neuromuscular junction disorders (e.g. myasthenia gravis or Lambert-Eaton syndrome) 
should be monitored closely and have an increased risk of clinically significant dysphagia 
and respiratory compromise.
Botulinum toxin type A contains albumin, which based on effective donor screening and 
manufacturing processes carries an extremely remote risk of transmission of viral diseases or 
Creutzfeldt-Jakob disease.
Specifically, for chronic migraine, it has been shown in double-blind, placebo-controlled effi-
cacy trials, which the discontinuation rate was 12% in the Botox®-treated group and 10% in the 
placebo-treated group. Discontinuations due to an adverse event were 4% in the Botox® group 
and 1% in the placebo group. The most frequent adverse events leading to discontinuation 
were neck pain, headache, worsening migraine, muscular weakness, and eyelid ptosis.
The most common reported adverse reactions following injection of Botox® for chronic 
migraine include neck pain (9%), headache (5%), migraine (4%), eyelid ptosis (4%), mus-
culoskeletal stiffness (4%), muscular weakness (4%), bronchitis (3%), myalgia (3%), muscu-
loskeletal pain (3%), injection site pain (3%), facial paresis (2%), muscle spasms (2%), and 
hypertension (2%). Other adverse reactions that occurred more frequently in the Botox® 
group compared to the placebo group at a frequency less than 1% include vertigo, dry eye, 
eyelid edema, dysphagia, eye infection, and jaw pain.
Safety and effectiveness in patients younger than 18 years have not been established. Clinical 
studies also did not include sufficient subjects older than 65 years to determine whether the 
response to treatment is different from younger patients.
6. Dosage and administration
Indication specific dosage and administration recommendations should be followed. In treat-
ing adult patients for one or more indications different than migraine, the maximum cumula-
tive dose should generally not exceed 360 Units, in a 3-month interval.
Onabotulinumtoxin-A vacuum-dried vials should be reconstituted prior to injection with 
sterile, non-preserved 0.9% Sodium Chloride Injection USP. For chronic migraines, the 
recommended dilution is 200 Units/4 mL or 100 Units/2 mL, with a final concentration of 5 
Units/0.1 mL. The recommended dose for treating chronic migraine is 155 Units administered 
intramuscularly rather than intradermal, avoiding the periosteum, eyelid region, and visible 
superficial blood vessels while using a sterile 30-gauge, 0.5-inch needle as 0.1 mL (5 Units) 
injections per each site for a total of 31 injection sites in the head and neck, divided across 
seven specific head/neck muscle areas. A 1-inch needle may be needed in the neck region for 
patients with thick neck muscles; the use of needles longer than 1-inch increases the risk of 
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complications such as pneumothorax, vascular injury, and spinal cord damage. Even though 
the FDA approved dosage is 155 Units distributed in 31 sites as in the PREEMPT trials, the 
total dose has ranged from 25 to 300 Units over several injection sites.
With the exception of the procerus muscle, which should be injected at one site (midline), all 
muscles should be injected bilaterally with half the number of injection sites administered to 
the left and half to the right side of the head and neck; even if the patient has strictly unilateral 
headaches. The recommended re-treatment schedule is every 12 weeks. Figure 1 shows the 
recommended injection sites for chronic migraine.
Botox dosing by muscle for chronic migraine is as follows: (1) frontalis muscle—20 Units 
divided in four sites distributed bilaterally; (2) corrugator muscles—10 Units divided in two 
Figure 1. Injection sites.
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sites distributed bilaterally; (3) procerus muscle—5 Units in one site; (4) occipitalis muscle—30 
Units divided in six sites distributed bilaterally; (5) temporalis muscles—40 Units divided in 
eight sites distributed bilaterally; (6) trapezius muscles—30 Units divided in six sites dis-
tributed bilaterally; and (7) cervical paraspinal muscle group—20 Units divided in four sites 
distributed bilaterally.
The target of these injections is superficial to the peripheral sensory nerves, namely the tri-
geminal nerve branches, the occipital nerves, and the cervical sensory rami from C3 to C5, 
rather than the muscles themselves.
Upper cervical-occipital muscles, especially the splenius capitis and splenius cervicis, may 
trigger migraine. Frequently, these muscles also contribute to pain and headache by irritating 
the adjacent greater occipital nerve and causing the concomitant neuralgic symptomatology. 
Thoracic paraspinal and periscapular muscles are frequently symptomatic and can also trig-
ger headache. Unwanted weakness of the supraspinatus and infraspinatus muscles, which 
form part of the rotator cuff, allows the humeral head to rise, while injected trapezius and 
levator scapulae may cause the acromion to sag inferiorly and anteriorly. This can result in 
painful shoulder impingement 8–10 days after injections.
Onabotulinumtoxin type A reaches its clinical effect at 7–10 days and plateaus at 3 weeks. The 
neuromuscular blocking action of BTX-A lasts 3–4 months; however, the reduction of pain 
can last substantially longer, and an effect more specific for migraine may continue to develop 
beyond 2–3 months after the injection session [35].
A combination of a fixed-dose/fixed-site injection plan and a follow-the-pain method is 
appropriate. Following this premise, Guyuron has identified trigger points and has proposed 
another method of peripheral nerve decompression, through surgical release of mechanical 
entrapment, reducing effectively migraine severity and frequency with surgical deactivation 
of peripheral trigger points. Even though other trigger point identification methods have 
been described, botulinum toxin type A injections can serve as a prognosticator of migraine 
surgery success because of its significant positive association with surgical outcomes [36–38].
Follow-the-pain injection sites are identified by history and examination of the cervical-
shoulder girdle and temporomandibular musculature being most useful for patients with 
tension-type headaches. These sites include the frontalis, temporalis, occipitalis, trapezius, 
splenius capitis, suboccipital, and cervical paraspinal muscles. Guyuron has identified four 
major and several minor trigger sites, and botulinum toxin type A injections for trigger site 
identification and migraine surgery planning are administered at one trigger site per visit 
based on the constellation of symptoms. The frontal trigger site (Site I) involves the supraor-
bital and supratrochlear nerves. In the temporal trigger site (Site II), the zygomaticotemporal 
branch of the trigeminal nerve is compressed by the temporalis muscle and the tight deep 
temporal fascia. In the rhinogenic trigger site (Site III), contact points among the septum, tur-
binates, and concha bullosa or sinus inflammation can irritate the trigeminal nerve, obviously 
when the symptoms suggest Site III as the main trigger, this site should not be injected. In the 
greater and/or third occipital nerves (Site IV), the semispinalis capitis muscle, fascial bands, 
and occipital artery could irritate the nerves triggering migraines. The minor triggers consist 
of the auriculotemporal nerve (Site V) and the lesser occipital nerve (Site VI) [39].
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When only a follow-the-pain approach is used in patients with migraine or migrainous 
headache, there is a risk for a poor cosmetic outcome and/or shifting of the headaches to the 
previously unaffected side. Even in these cases, cosmetic effects in the frontal region need to 
be obtained, which also assure good compliance with continued treatment; but asymmetric 
injections can be given in the temporalis, occipitalis, splenius capitus, cervical, and subcervical 
paraspinal muscles. The doses injected in the cervical-shoulder girdle muscles are low to pre-
vent any possible weakness that could cause headache. Patients need to be carefully assessed 
for associated cervical dystonia, which requires injection of the dystonic muscles. Current 
available data do not appear to indicate a dose-response benefit from BTX-A injection therapy.
For patients with migraine or migrainous headache features identified by history, treatment 
with a fixed-site approach may be required for successful results.
Therefore, further randomized, placebo-controlled clinical trials are needed to identify the 
optimal dosing regimen and injection sites. However, some studies have reported greater 
efficacy with repeated dosing [8, 14].
Migraine improvement can be monitored with the use of a diary or another self-reporting 
method. Progress is indicated by reduction of oral prophylactic medications, improved 
response from abortive therapies, as well as reduced frequency, intensity, and severity of 
migraine headache symptoms. Nonpharmacologic headache therapies, such as biofeedback, 
cognitive-behavioral pain management strategies, and relaxation therapies, which were pre-
viously ineffective, may prove more successful after BTX chemodenervation and should be 
reconsidered as adjuncts to treatment [35].
Currently, only Botox® has been approved by the FDA for the treatment of chronic migraines, 
but in studies of botulinum toxin type A, Dysport® has shown efficacy when administered for 
tension-type headache using a dosage of 200–500 Units per application.
After injection, patients should be informed that (1) from time to injection to symptomatic 
benefit is between 3 and 14 days, peaking at 3 weeks, (2) duration of benefit is 12–16 weeks, 
(3) maximum effect may take several treatments, (4) duration of reduction in headache symp-
toms may not be synchronous with the return of muscle function, and (5) postinjection site 
blebs in the forehead region will disappear within a few hours and will reduce the hyperfunc-
tional lines of the face in 3–5 days.
Patients should be instructed on keeping headache diaries, which document the frequency 
and location of headache, severity, and medications used over a 4-month period. The Migraine 
Disability Assessment (MIDAS) can be used as a measure of treatment success. Objective 
measurements of treatment effectiveness are important, so that clinical response can be evalu-
ated and future treatment sessions can be modified as necessary [30].
7. Efficacy
Guidelines indicate that quality clinical trials in patients with migraine should always be 
double-blind, randomized, placebo-controlled trials [40]. Clinical evidence supporting the 
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use of botulinum toxin injections is mixed. Binder demonstrated that 51% of migraineurs 
reported complete response, and an additional 38% reported partial responses for a mean 
of 4.1 and 2.7 months, respectively [30]. Data from the double-blind phase of studies dem-
onstrate significant improvement with onabotulinumtoxin A versus placebo observed over 
24 weeks of treatment, demonstrating that the benefits persist over 56 weeks of treatment 
using measures of headache impact (HIT-6) and quality of life questionnaires (HRQoL). 
Patients who switched from placebo to onabotulinumtoxin A at 24 weeks experienced sig-
nificant improvements from baseline at a rate of change not different than observed among 
patients that received onabotulinumtoxin A from the start of the double-blind period. This 
indicates that efficacy persists even if the treatment is delayed.
All patients improved, as indicated by a change from baseline in the frequency of moderate 
to severe migraines. Botulinum toxin type A is a safe treatment that significantly reduces 
migraine frequency and severity. It is still discussed to what extent the way of application 
of botulinum toxin may influence its efficacy, and in most studies, the fixed-site approach 
has been employed. This creates a systematical approach injecting the same predetermined 
sites with predetermined doses. For the follow-the-pain method, the authors conducting tri-
als have been acknowledged that their results do not confirm efficacy but may be useful for 
chronic migraines [11].
Silberstein published the first placebo-controlled, double-blind study in migraine patients 
with 123 patients who were randomized into three groups and treated with placebo, 25, or 
75 Units of Botox®. The treatment with 25 Units was superior to placebo in reducing the fre-
quency of the attacks but no different than the 75 U group [8].
Multiple studies have shown a tendency to reduce headache days in distinct period of time 
but have failed to reach criteria for statistical significance [34, 41–43].
Dodick has found a statistically significant difference in an analysis of 228 patients without 
prophylactic medication [12]. The breakthrough of onabotulinumtoxin-A in the treatment of 
chronic migraine came in 2010, when Phase III Research Evaluating Migraine Prophylaxis 
Therapy (PREEMPT) study group published the results of the PREEMPT I and PREEMPT 
II trials, totaling 1384 patients who were included in a 28-day baseline screening period, a 
24-week double-blind, parallel-group, placebo-controlled phase, and a 32-week open-label 
phase. Both studies completed three injection trials, with the same study design but different 
endpoint conclusions.
In the PREEMPT I trial, significant differences were found in the reduction of headache and 
migraine days but missed the amount of migraine episodes. The PREEMPT II confirmed the 
efficacy in the reduction of headache days [12, 16]. The positive results of the two PREEMPT 
trials led to approval of onabotulinumtoxin-A in September 2011 by the US FDA and many 
other registration authorities worldwide.
Medication overuse is a major problem in chronic migraine patients, and the PREEMPT 
pooled data show effectiveness in a reduction in headache days and a reduction in medication 
overuse. Beside reduction in headache frequency and severity, botulinum toxin also improves 
quality of life [3, 4]. In a more recent study [44], it was demonstrated that monthly headache 
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days, migraine days, days with nausea/vomiting, and days with intake of pain medications 
were significantly reduced after the first treatment, maintaining such effect throughout the 
entire study period. Also health-related and migraine-related quality of life improved after 
the treatment. Patients also had a decrease in depression symptoms, theoretically mediated 
by improving quality of life.
In all the mentioned studies, approximately a 10% of patients did not respond to treatment 
with botulinum toxin. The development of antibodies, intrinsic worsening of migraine, and 
an initial placebo effect have also been discussed as causes of resistance to treatment [45].
8. Conclusions
Migraine is a major cause of disability worldwide. Chronic migraine can reduce quality of life 
and is one of the most prevalent conditions. Physicians treat day-to-day and must precisely 
diagnose and effectively treat headache disorders. An adequate examination will guide to a 
specific disorder, so the indicated therapeutic plan can be started to assure patient satisfac-
tion. Acute medications have shown variable efficacy, and patients commonly seek preventive 
therapy to avoid the inconvenient impairment chronic migraines that can cause. Botulinum 
neurotoxin, even if not fully comprehended in its precise pathophysiology for the treatment 
of pain, has provided relief from headache pain, reducing severity, frequency, and duration 
of episodes and improving quality of life. Currently, the FDA has approved only a fixed-
point technique; together with the follow-the-pain injection, technique can relief migraine 
for 12 weeks or more. Further studies have to be conducted to demonstrate the mechanism 
of action pathways and to perfect the administration, but currently, botulinum toxin is a safe, 
effective, and with minimal adverse effects to be considered in migraine therapy.
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